Following the rapid label expansion of drugs such as semaglutide and tirzepatide in recent years, drug developers have broadly adopted multi-indication strategies for obesity and related comorbidities. An ICON survey of 155 developers focused on these therapeutic areas reflects this growing trend. 

Survey respondents – whose work spans obesity, cardiovascular, hepatic, and renal comorbidities, as well as neurological and behavioural indications – reported that the widespread adoption of multi-indication development is being driven by compelling market forces and a deeper understanding of interrelated disease mechanisms. Overall, 95% reported experience with multi-indication development, and 83% are actively implementing such strategies. More than three in four believe multi-indication drugs would ultimately reduce healthcare system costs.